|
|
|
|
|
06.11.25 - 22:06
|
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025
Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss
Initiated Manufacturing Scale Project in Type 1 Diabetes Cell Therapy
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
“It has been a productive third quarter for the Lineage team,” stated Brian M. Culley, Lineage CEO. “Last quarter, I outlined five areas of focus through the end of this year, and I am pleased to report that we delivered on several of these during the thi...
|
|
|
|
|
22.10.25 - 12:36
|
Impilo acquires Oticon Medical from Demant (Cision)
|
|
|
Stockholm, 2025-10-22 - Impilo is pleased to announce that it has agreed to acquire Oticon Medical, a global leader in bone-anchored hearing solutions (BAHS), from Demant A/S. This transformative transaction represents the first investment from Impilo's recently raised Fund II and marks the beginning of an exciting new chapter for Oticon Medical. Building on the company's legacy of innovation and patient care, Impilo will support Oticon Medical in its transition to a standalone company while accelerating growth, advancing next-generation technologies, and strengthening its position as a...
|
|
|
|
|
04.09.25 - 23:51
|
XETR: NEW INSTRUMENT AVAILABLE - 05.09.2025 - DK0060738599 (XETRA)
|
|
|
Das Instrument WDH1 DK0060738599 DEMANT AS A DK 0,2 EQUITY hat seinen ersten Handelstag am 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG SKA0, SettlCurr EUR, CCP Y
The instrument WDH1 DK0060738599 DEMANT AS A DK 0,2 EQUITY has its first trading date on 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG SKA0, SettlCurr EUR, CCP Y...
|
|
|
26.08.25 - 14:03
|
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss (Business Wire)
|
|
|
Three-year term intended to advance preclinical development of ReSonance
Up to $12 million of development costs to be contributed by William Demant Invest
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious neurological and ophthalmic conditions, today announced that it has entered into a research collaboration with and through an investment from William Demant Invest A/S (WDI). WDI is an evergreen investor and the holding company for William Demant Foundation's investment activities – a majority shareholder of the world-leading hearing healthcare company, Demant A/S.
The parties will jointly advance Lineage's auditory neuronal cell transplant, ReSonance (ANP1), for the treatment of hearing loss. The multi-year research collaboration covers preclinical development activities, including cell manufacturing, p...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
